Myxopapillary Ependymoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MYX001 MIFTS: 47	Myxopapillary Ependymoma Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Myxopapillary Ependymoma

MalaCards integrated aliases for Myxopapillary Ependymoma:

Name: Myxopapillary Ependymoma ¹² ⁵⁴ ⁶⁰ ¹⁵ ⁷⁴

Ependymoma Myxopapillary ⁵⁶

Characteristics:

Orphanet epidemiological data:

⁶⁰

myxopapillary ependymoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adolescent,All ages,Childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³⁵

Neoplasms

Neoplasms of uncertain or unknown behaviour

Neoplasm of uncertain or unknown behaviour of brain and central nervous system

Neoplasm of uncertain or unknown behaviour: Brain, unspecified

External Ids:

Disease Ontology ¹² DOID:5075

MeSH ⁴⁵ D004806

NCIt ⁵¹ C3697

SNOMED-CT ⁶⁹ 1623000

ICD10 via Orphanet ³⁵ D43.2

UMLS via Orphanet ⁷⁵ C0205769

Orphanet ⁶⁰ ORPHA251643

SNOMED-CT via HPO ⁷⁰ 126488004 22631008 249497008 more

UMLS ⁷⁴ C0205769

Sources

Summaries for Myxopapillary Ependymoma

NIH Rare Diseases : ⁵⁴ Myxopapillary ependymoma (MEPN) is a slow-growing ependymoma (a type of glioma, which is a tumor that arises from the supportive tissue of the brain and spinal cord). They tend to occur in the lower part of the spinal column and are usually considered to be benign, low-grade or grade I tumors. The age of diagnosis ranges from 6 to 82 years. Symptoms of an ependymoma are related to the location and size of the tumor and may include nausea, vomiting, headache, pain, numbness, bowel or bladder symptoms, and various other signs and symptoms. The cause of ependymomas is unknown. They are known to recur locally (more commonly in individuals diagnosed in childhood). Treatment may vary depending on the location, grade, and whether the tumor has spread to the spine, but typically includes aggressive surgery. Management may also include chemotherapy and radiation therapy.

MalaCards based summary : Myxopapillary Ependymoma, also known as ependymoma myxopapillary, is related to ependymoma and secretory meningioma, and has symptoms including back pain An important gene associated with Myxopapillary Ependymoma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Fentanyl and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and skin, and related phenotypes are ependymoma and abnormal conus terminalis morphology

Sources

Related Diseases for Myxopapillary Ependymoma

Diseases related to Myxopapillary Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)

#	Related Disease	Score	Top Affiliating Genes
1	ependymoma	31.3	GFAP MUC1 S100B VIM
2	secretory meningioma	30.5	MUC1 VIM
3	neurofibroma	30.4	MUC1 S100B
4	chordoma	29.9	GFAP MUC1 S100B VIM
5	chordoid meningioma	29.5	GFAP MUC1 S100B VIM
6	anaplastic ependymoma	29.5	GFAP MUC1 S100B VIM
7	benign ependymoma	11.9
8	siderosis	10.4
9	cutaneous leiomyosarcoma	10.3	GFAP MUC1
10	papillary ependymoma	10.3	GFAP S100B
11	lipomatosis, multiple	10.3
12	pilonidal sinus	10.3
13	meningioma, familial	10.3
14	pleomorphic lipoma	10.3
15	spinal meningioma	10.3
16	cauda equina syndrome	10.3
17	tethered cord syndrome	10.3
18	superficial siderosis	10.3
19	gemistocytic astrocytoma	10.3	GFAP S100B
20	localized hypertrophic neuropathy	10.2	MUC1 S100B
21	sclerosing perineurioma	10.2	MUC1 S100B
22	dysembryoplastic neuroepithelial tumor	10.2	GFAP S100B
23	reticular perineurioma	10.2	MUC1 S100B
24	non-functioning pituitary adenoma	10.2	MUC1 S100B
25	functioning pituitary adenoma	10.2	MUC1 S100B
26	pineocytoma	10.2	GFAP S100B
27	epithelioid malignant peripheral nerve sheath tumor	10.2	MUC1 S100B
28	aggressive digital papillary adenocarcinoma	10.2	MUC1 S100B
29	spiradenoma	10.2	MUC1 S100B
30	spinal cancer	10.2	GFAP HOXB13
31	subependymal giant cell astrocytoma	10.2	GFAP S100B
32	traumatic brain injury	10.2	GFAP S100B
33	brain injury	10.2	GFAP S100B
34	meningeal melanocytoma	10.2	MUC1 S100B
35	lung combined type small cell carcinoma	10.2	GFAP NCAM1
36	intraneural perineurioma	10.2	MUC1 S100B
37	neuroma	10.2	GFAP S100B
38	ovarian serous cystadenofibroma	10.2	MUC1 NCAM1
39	cystadenofibroma	10.1	MUC1 NCAM1
40	transitional meningioma	10.1	MUC1 NCAM1
41	ganglioglioma	10.1	GFAP S100B
42	subependymoma	10.1	GFAP NCAM1
43	pseudomyxoma peritonei	10.1	CA2 MUC1
44	epidermoid cysts	10.1
45	renal cell carcinoma, nonpapillary	10.1
46	down syndrome	10.1
47	chondrosarcoma	10.1
48	temporal lobe epilepsy	10.1
49	paraganglioma	10.1
50	colorectal adenocarcinoma	10.1

Graphical network of the top 20 diseases related to Myxopapillary Ependymoma:

Sources

Symptoms & Phenotypes for Myxopapillary Ependymoma

Human phenotypes related to Myxopapillary Ependymoma:

⁶⁰ ³³ (show all 12)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	ependymoma ⁶⁰ ³³	obligate (100%)	Obligate (100%)	HP:0002888
2	abnormal conus terminalis morphology ⁶⁰ ³³	hallmark (90%)	Very frequent (99-80%)	HP:0031938
3	vomiting ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0002013
4	headache ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0002315
5	unsteady gait ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0002317
6	abnormal large intestine physiology ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0012700
7	neck pain ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0030833
8	autonomic bladder dysfunction ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0005341
9	neoplasm of the skin ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0008069
10	abnormal sacrum morphology ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0005107
11	abnormality of the auditory canal ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0000372
12	neoplasm of the central nervous system ⁶⁰		Frequent (79-30%)

UMLS symptoms related to Myxopapillary Ependymoma:

back pain

GenomeRNAi Phenotypes related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased cell migration	GR00055-A-1	8.8	MUC1 NCAM1 VIM

Sources

Drugs & Therapeutics for Myxopapillary Ependymoma

Drugs for Myxopapillary Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Donepezil

Approved

Phase 3,Phase 2

120014-06-4

3152

Dopamine

Approved

Phase 3,Early Phase 1

62-31-7, 51-61-6

681

Methylphenidate

Approved, Investigational

Phase 3

113-45-1

4158

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Narcotics

Phase 3

Adjuvants, Anesthesia

Phase 3

Analgesics

Phase 3

Anesthetics, Intravenous

Phase 3

Liver Extracts

Phase 3,Phase 2,Phase 1

Anesthetics, General

Phase 3

Anesthetics

Phase 3

Analgesics, Opioid

Phase 3

Central Nervous System Depressants

Phase 3

Peripheral Nervous System Agents

Phase 3

Cola

Phase 3,Phase 1

Cholinesterase Inhibitors

Phase 3,Phase 2

Neurotransmitter Agents

Phase 3,Phase 2,Early Phase 1

Nootropic Agents

Phase 3,Phase 2

Cholinergic Agents

Phase 3,Phase 2

Central Nervous System Stimulants

Phase 3,Phase 2

Dopamine Agents

Phase 3,Early Phase 1

Dexmethylphenidate Hydrochloride

Phase 3

Dopamine Uptake Inhibitors

Phase 3

Neurotransmitter Uptake Inhibitors

Phase 3

Temozolomide

Approved, Investigational

Phase 2,Phase 1

85622-93-1

5394

Etoposide

Approved

Phase 2

33419-42-0

36462

Cisplatin

Approved

Phase 2,Phase 1

15663-27-1

2767 441203 84093

Modafinil

Approved, Investigational

Phase 2

68693-11-8

4236

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Lenograstim

Approved, Investigational

Phase 2,Phase 1

135968-09-1

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

126941

leucovorin

Approved

Phase 2

58-05-9

143 6006

Sodium Citrate

Approved, Investigational

Phase 2

68-04-2

Carboplatin

Approved

Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Topotecan

Approved, Investigational

Phase 2

119413-54-6, 123948-87-8

60700

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

Iodine

Approved, Investigational

Phase 1, Phase 2,Phase 2

7553-56-2

807

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

5743

Promethazine

Approved, Investigational

Phase 2

60-87-7

4927

Diphenhydramine

Approved, Investigational

Phase 2

147-24-0, 58-73-1

3100

Acetaminophen

Approved

Phase 2

103-90-2

1983

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 2

77-92-9

311

Doxil

Approved June 1999

Phase 2

31703

Antineoplastic Agents, Alkylating

Phase 2,Phase 1

Alkylating Agents

Phase 2,Phase 1

Interventional clinical trials:

(show all 42)

#	Name	Status	NCT ID	Phase	Drugs
1	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
2	Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors	Completed	NCT00369785	Phase 3	donepezil hydrochloride;Placebo
3	Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors	Terminated	NCT00031798	Phase 3	methylphenidate hydrochloride
4	Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas	Completed	NCT00002876	Phase 2	cisplatin;etoposide
5	Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors	Completed	NCT01032200	Phase 2	Armodafinil
6	Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma	Completed	NCT00006258	Phase 2	cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
7	Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors	Completed	NCT00541138	Phase 2	carboplatin;tamoxifen citrate;topotecan hydrochloride
8	Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma	Completed	NCT00498927	Phase 2	temozolomide
9	Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas	Completed	NCT00274755	Phase 2	chemotherapy
10	Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor	Completed	NCT00070161	Phase 2	donepezil hydrochloride
11	Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers	Completed	NCT00002752	Phase 1, Phase 2
12	Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	Completed	NCT00002608	Phase 2	cisplatin;doxorubicin hydrochloride;tamoxifen citrate
13	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer	Active, not recruiting	NCT00445965	Phase 2
14	Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors	Withdrawn	NCT00005083	Phase 2
15	Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas	Unknown status	NCT00083096	Phase 1	lonafarnib;temozolomide
16	RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma	Completed	NCT01119599	Phase 1	Gamma-Secretase Inhibitor RO4929097;Temozolomide
17	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction	Completed	NCT00030498	Phase 1	erlotinib hydrochloride
18	A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors	Completed	NCT00784914	Phase 1	temsirolimus
19	Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma	Completed	NCT00730613	Phase 1
20	Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment	Completed	NCT00544284	Phase 1	bortezomib;temozolomide
21	Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers	Completed	NCT00498979	Phase 1	cisplatin;sodium stibogluconate;dacarbazine;vinblastine
22	Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma	Completed	NCT00401024	Phase 1	imatinib mesylate
23	Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas	Completed	NCT00002753	Phase 1
24	Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer	Completed	NCT00006368	Phase 1
25	Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor	Completed	NCT00069940	Phase 1
26	Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors	Completed	NCT00008086	Phase 1	carboplatin
27	Thalidomide and Docetaxel in Treating Patients With Advanced Cancer	Completed	NCT00049296	Phase 1	docetaxel;thalidomide
28	CC-5013 in Treating Patients With Recurrent Glioma	Completed	NCT00036894	Phase 1	lenalidomide
29	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma	Completed	NCT00020579	Phase 1	entinostat
30	Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas	Completed	NCT00019019	Phase 1	carboxyamidotriazole;paclitaxel
31	Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer	Completed	NCT00003022	Phase 1
32	Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors	Terminated	NCT00110032	Phase 1	EF5
33	Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Terminated	NCT00003567	Phase 1	O6-benzylguanine;carmustine;temozolomide
34	Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma	Completed	NCT00005082	Not Applicable
35	Study of Blood and Cheek Cell Samples From Patients With Glioma	Completed	NCT01009307
36	Study of Tissue Samples From Patients With Glioma or Other Brain Tumors	Completed	NCT00967200
37	Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors	Completed	NCT00499798
38	Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders	Completed	NCT00255671
39	Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma	Active, not recruiting	NCT01165632	Early Phase 1	fluorine F 18 fluorodopa
40	Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma	Terminated	NCT00430079	Not Applicable	etanidazole
41	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	Withdrawn	NCT02194452	Not Applicable
42	Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors	Withdrawn	NCT00005790	Not Applicable

Search NIH Clinical Center for Myxopapillary Ependymoma

Sources

Genetic Tests for Myxopapillary Ependymoma

Sources

Anatomical Context for Myxopapillary Ependymoma

MalaCards organs/tissues related to Myxopapillary Ependymoma:

⁴²

Brain, Spinal Cord, Skin, Temporal Lobe, Bone, Kidney, Pituitary

Sources

Publications for Myxopapillary Ependymoma

Articles related to Myxopapillary Ependymoma:

(show top 50) (show all 186)

#	Title	Authors	Year
1	Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature. ( 30321682 )	Pusat S...Erdo?an E	2019
2	Myxopapillary Ependymoma. ( 30844350 )	Frazier AA	2019
3	Resection of Myxopapillary Ependymoma of the Filum Terminale: 2-Dimensional Operative Video. ( 31073602 )	Mastorakos P...Nduom EK	2019
4	Myxopapillary ependymoma with anaplastic features: A case report with review of the literature. ( 30294495 )	Huynh TR...Lekovic G	2018
5	Isolated myxopapillary ependymoma of the fourth ventricle: case report and review of literature. ( 30317890 )	Kumaria A...Dow GR	2018
6	An Extremely Rare Case of Back and Hip Pain due to the Metastasis of Late Recurrent Myxopapillary Ependymoma to the Inguinal Lymph Node. ( 29166763 )	Ekemen S...Ince U	2018
7	Metastases of spinal myxopapillary ependymoma: unique characteristics and clinical management. ( 29219779 )	Kraetzig T...Laufer I	2018
8	Myxopapillary Ependymoma of Lumbar Soft Tissue: A Case Report With Gene Expression Evaluation. ( 29254456 )	Shelekhova KV...Matsko DE	2018
9	Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. ( 29270703 )	Fujiwara Y...Adachi N	2018
10	Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. ( 29380114 )	Vetrano IG...Valentini LG	2018
11	Teaching Case 2-2018: Sclerosing myxopapillary ependymoma mimicking whorling-sclerosing meningioma. ( 29436365 )	Lang J...Gelpi E	2018
12	Anaplastic myxopapillary ependymoma in an infant: Case report and literature review. ( 28580214 )	Trivedi D...Xiong Z	2017
13	Spinal myxopapillary ependymoma presenting with low back pain and subarachnoid hemorrhage. ( 28737370 )	Pilloni G...Garbossa D	2017
14	Occipital Intraparenchymal Myxopapillary Ependymoma: Case Report and Literature Review. ( 29114296 )	Mewada TB...Singh D	2017
15	Primary Seeding of Myxopapillary Ependymoma: Different Disease in Adult Population? Case Report and Review of Literature. ( 28040529 )	Khan NR...Arnautovi? K	2017
16	Spinal myxopapillary ependymoma with interval drop metastasis presenting as cauda equina syndrome: case report and review of literature. ( 27757435 )	Rege SV...Songara A	2016
17	Synchronous Sacrococcygeal Myxopapillary Ependymoma and Chordoma. ( 26464159 )	Vroobel K...Thway K	2016
18	An unusual cause of low back pain in a young adult: myxopapillary ependymoma of the filum terminale. ( 26657487 )	Demir MK...Konya D	2016
19	Intradural extramedullary non-myxopapillary ependymoma with a lumbar nerve root involvement in a Japanese man. ( 26852964 )	Funao H...Koyanagi T	2016
20	Surgical treatment for posttraumatic hemorrhage inside a filum terminale myxopapillary ependymoma: a case report and literature review. ( 27015688 )	Morimoto D...Morita A	2016
21	Lumbar corpectomy for correction of degenerative scoliosis from osteoradionecrosis reveals a delayed complication of lumbar myxopapillary ependymoma. ( 27056674 )	Palejwala SK...Dumont TM	2016
22	Spinal myxopapillary ependymoma in an adult male presenting with recurrent acute low back pain: a case report. ( 27092234 )	Petersen D...Lystad RP	2016
23	Concomitant Double Tumors of Myxopapillary Ependymoma Presented at Cauda Equina-Filum Terminale in Adult Patient. ( 27123029 )	Yener U...?zgen S	2016
24	Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. ( 27306443 )	Bates JE...Milano MT	2016
25	Uterine Cervix Metastasis of Myxopapillary Ependymoma Originated from the Spinal Cord. ( 27403397 )	G?zin K...?zkanl? ?	2016
26	Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. ( 27423644 )	Lucchesi KM...DiLuna ML	2016
27	Primary multifocal myxopapillary ependymoma of the filum terminale. ( 26154385 )	Khalatbari MR...Shobeiri E	2016
28	Unspecific clinical manifestation of cauda equina myxopapillary ependymoma. ( 26396623 )	Kariev GM...Rasulov SO	2015
29	Outcome predictors in the management of spinal myxopapillary ependymoma: an integrative survival analysis. ( 25108296 )	Kukreja S...Nanda A	2015
30	A rare case of extramedullary myxopapillary ependymoma. ( 25280929 )	Menzilcioglu MS...Citil S	2015
31	Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. ( 25301811 )	Weber DC...Li J	2015
32	Myxopapillary ependymoma: Lesser known cytomorphologic features. ( 25948946 )	Choudhury M...Nain M	2015
33	Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. ( 26235025 )	Abdulaziz M...Clarke MJ	2015
34	Disseminated adult spinal extramedullary myxopapillary ependymoma. ( 26253989 )	Tokta? ZO...Konya D	2015
35	Disseminated spinal myxopapillary ependymoma in an adult at initial presentation: a case report and review of the literature. ( 24460084 )	Straus D...O'Toole JE	2014
36	Lumbar spine neuroarthropathy (Charcot joint) caused by a myxopapillary ependymoma. ( 24477624 )	Chamberlain MC...Maravilla KR	2014
37	Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. ( 24818785 )	Tsai CJ...Li J	2014
38	Spinal drop metastasis in myxopapillary ependymoma: a case report and a review of treatment options. ( 25002955 )	Bates JE...Milano MT	2014
39	Myxopapillary ependymoma in children: a study of 11 cases and a comparison with the adult experience. ( 25066546 )	Cimino PJ...Dehner LP	2014
40	Pediatric myxopapillary ependymoma treated with subtotal resection and radiation therapy: a case report and review of the literature. ( 25082377 )	Shirasawa H...Nakamura M	2014
41	Myxopapillary ependymoma of filum terminale. ( 25181852 )	Koev IG...Kitov BD	2014
42	Spontaneous rupture and hemorrhage of myxopapillary ependymoma of the filum terminale: a case report and literature review. ( 25264068 )	Tonogai I...Sairyo K	2014
43	Myxopapillary ependymoma masquerading as subcutaneous sacrococcygeal non-healing ulcer: case report. ( 25266190 )	Zaidi SN...Al-Rikabi AC	2014
44	Myxopapillary ependymoma of the cauda equina in a 5-year-old boy. ( 25558331 )	Uehara M...Kato H	2014
45	Myxopapillary ependymoma of the conus medullaris presenting with intratumoral hemorrhage during weight lifting in a teenager. ( 23821248 )	Khalatbari MR...Moharamzad Y	2014
46	The nature of double concomitant myxopapillary ependymoma: report of a case. ( 23904042 )	Salom?o JF...Cervante TP	2014
47	Cytopathologic characteristics and differential diagnostic considerations of osteolytic myxopapillary ependymoma. ( 23913845 )	Hayashi T...Matsunaga T	2014
48	Primary cerebral myxopapillary ependymoma presenting with intratumoral hemorrhage. ( 24229008 )	Khalatbari MR...Moharamzad Y	2014
49	Clinicopathological features of myxopapillary ependymoma. ( 24332590 )	Wang H...Zhou X	2014
50	Concomitant intramedullary pilocytic astrocytoma and conus medullaris myxopapillary ependymoma: a case report. ( 21688235 )	Oukabli M...Abderrahmane A	2013

Sources

Genes for Myxopapillary Ependymoma

Genes related to Myxopapillary Ependymoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	31.35	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	19521276
2	S100B	S100 Calcium Binding Protein B	Protein Coding	24.55	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	7504258 19521276
3	CA2	Carbonic Anhydrase 2	Protein Coding	20.71	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	17.52	GeneCards inferred via : Publications (show sections)
5	NCAM1	Neural Cell Adhesion Molecule 1	Protein Coding	17.17	GeneCards inferred via : Publications (show sections)
6	VIM	Vimentin	Protein Coding	17.17	GeneCards inferred via : Publications (show sections)
7	HOXB13	Homeobox B13	Protein Coding	15.36	DISEASES inferred ¹⁵

Sources

Variations for Myxopapillary Ependymoma

Sources

Expression for Myxopapillary Ependymoma

Search GEO for disease gene expression data for Myxopapillary Ependymoma.

Sources

Pathways for Myxopapillary Ependymoma

Pathways related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neuroscience ⁴	11.79	CA2 GFAP NCAM1 S100B
2	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁶	10.82	GFAP NCAM1 S100B VIM
3	Cell adhesion_Cell-matrix glycoconjugates ²³	10.75	MUC1 NCAM1

Sources

GO Terms for Myxopapillary Ependymoma

Biological processes related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	response to wounding	GO:0009611	9.43	GFAP HOXB13
2	negative regulation of neuron projection development	GO:0010977	9.4	GFAP VIM
3	long-term synaptic potentiation	GO:0060291	9.37	GFAP S100B
4	morphogenesis of an epithelium	GO:0002009	9.32	CA2 HOXB13
5	intermediate filament organization	GO:0045109	9.26	GFAP VIM
6	astrocyte development	GO:0014002	9.16	GFAP VIM
7	Bergmann glial cell differentiation	GO:0060020	8.96	GFAP VIM
8	intermediate filament-based process	GO:0045103	8.62	GFAP VIM

Sources

Sources for Myxopapillary Ependymoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia